Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRIMedical - Devices
+$0.84 today
- Market cap
- $1.35B
- Beta
- 2.18
- P/E (TTM)
- -34.3
- EPS (TTM)
- -$0.28
Volume 0.26M
Average 0.92M
LMRI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Lumexa Imaging Holdings, Inc. Common StockNASDAQ: LMRI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation of $12.27M in Q1 FY2026
Q1 FY2026 stock-based compensation was $12.27M.
Context
- Stock-based compensation amounted to 4.1% of revenue in FY2025, down 1.9 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 41.6M USD
- Year-over-year change
- -26.6%
- 2-year CAGR
- -13.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.6M | -26.6% |
| FY2024 | 2024-12-31 | 56.65M | +2.5% |
| FY2023 | 2023-12-31 | 55.3M | — |
Stock-Based Compensation vs competitors
How LMRI compares with its peers on the latest reported figures
- LMRI's FY2025 stock-based compensation of $41.6M is the smallest of the 2 companies compared; the peer median is $60.26M.
- Its year-over-year change of -26.6% is the lowest of 2, against a peer median of +10.1%.
- Stock-based compensation amounts to 4.1% of revenue for LMRI, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.26M | +10.1% | +31.9% | 2.5% | |
LMRILumexa Imaging Holdings, Inc. Common Stock | FY2025 | $41.6M | -26.6% | — | 4.1% |
| Peer median (excluding LMRI) | $60.26M | +10.1% | +31.9% | 2.5% | |
Competitors are the stored peer set for LMRI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (122.23M) | (94.1M) | (47.1M) |
| Depreciation & Amortization | 72.14M | 57.16M | 55.39M |
| Deferred Income Tax | 611K | 9.75M | 8.08M |
| Stock-Based Compensation | 55.3M | 56.65M | 41.6M |
| Change in Working Capital | (4.14M) | (2.6M) | (44.35M) |
| Accounts Receivables | (15.3M) | (5.32M) | (14.01M) |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 4.76M | 2.95M | 14.42M |
| Other Working Capital | 6.4M | (225K) | (44.75M) |
| Other Non-Cash Items | 35.83M | 13.86M | 3.46M |
| Operating Cash Flow | 37.51M | 40.73M | 17.07M |
| Capital Expenditures | (24.01M) | (27.77M) | (23.48M) |
| Acquisitions (Net) | (5.65M) | 5.13M | 2.64M |
| Purchases of Investments | 0 | 0 | (123K) |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 361K | 0 |
| Investing Cash Flow | (29.66M) | (22.28M) | (20.96M) |
| Debt Repayment | (10.91M) | (12.67M) | (392.83M) |
| Common Stock Issued | 2.26M | 673K | 427.81M |
| Common Stock Repurchased | (118K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | (506K) | 1.6M |
| Financing Cash Flow | (8.77M) | (12.5M) | 36.58M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (912K) | 5.95M | 32.7M |
| Free Cash Flow | 13.51M | 12.95M | (6.4M) |
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
Intrinsic Alpha fair value
Locked
Current Price
$14.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.